| |
| |
|
| |
|
|
|
| |
Content for site developed under the guidance of the TRACK Advisory Council.
|
|
 |
|
| |
 |
|
|
|
| | | | |
| | |
| |
|
| HARDWARE AND SOFTWARE SPECIFICATIONS NEEDED TO VIEW SITE | 
Printer-friendly version | This course requires Windows Operating Systems (95/98, NT, 2000, ME, XP), version 5.5 browsers or higher from Microsoft or Netscape.
Certain activities may require additional software to view multimedia, presentation, or printable versions of the content. These activities will be marked as such and will provide links to the required software. That software may be: Macromedia Flash, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, and Real Networks Real One Player.
| Back to top  | | | ACCREDITATION STATEMENT | This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Elsevier Office of Continuing Medical Education (EOCME) and Excerpta Medica, Inc. The EOCME is accredited by the ACCME to provide continuing medical education (CME) for physicians. | | Back to top | | | CREDIT DESIGNATION STATEMENT | The EOCME designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. | | Back to top | | | DISCLOSURES | As a sponsor accredited by the ACCME, it is the policy of the EOCME to require the disclosure of anyone who is in a position to control the content of an educational activity. All relevant financial relationships with any commercial interests and/or manufacturers must be disclosed to participants at the beginning of each activity. The faculty of this CME activity disclose the following: | Faculty Member | | Manufacturer | | Relationship | | Andrea Natale, MD | | Nothing to Disclose | | Nothing to Disclose | | Allan L. Klein, MD | | sanofi-aventis U.S. | | Grants/Research Support | | Boris S. Lowe, MD | | Nothing to Disclose | | Nothing to Disclose | | Mina K. Chung, MD | | Reliant Pharmaceuticals, Guidant, Medtronic, St. Jude, Biotronik | | Grants/Research Support | | | | CryoCath Technologies | | Consultant | | | | Reliant Pharmaceuticals, Guidant, Medtronic | | Speaker’s Bureau | | Jack Hirsh, MD | | Nothing to Disclose | | Nothing to Disclose | | Geno J. Merli, MD | | sanofi-aventis U.S., AstraZeneca | | Grants/Research Support, Consultant, Speaker’s Bureau | | | | Bacchus Vascular, Inc. | | Consultant | | | | Bayer Pharmaceuticals Corporation | | Grants/Research Support | | Deepak L. Bhatt, MD | | Bristol-Myers Squibb, sanofi-aventis U.S., The Medicines Company | | Speaker’s Bureau | | | | AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Eisai, GlaxoSmithKline, Millennium, ParinGenix, Protein Design Labs, sanofi-aventis U.S., Schering-Plough, The Medicines Company | | Consultant/Advisory Board | | Activity Director | | | | | | Lawrence DeCaria, PharmD | | Excerpta Medica | | Nothing to Disclose | | Jennifer DiBenedetto | | EOCME | | Nothing to Disclose |
| | Back to top | | | RESOLUTION OF CONFLICT OF INTEREST | The EOCME has implemented a process to resolve conflict of interest for each CME activity. In order to help ensure content objectivity, independence, and fair balance, and to ensure that the content is aligned with the interest of the public, the EOCME has resolved the conflict by conducting peer review. | | Back to top | | | UNAPPROVED/OFF-LABEL USE DISCLOSURE | The EOCME requires CME faculty to disclose to the participants:
1. When products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not US Food and Drug Administration [FDA] approved); and
2. Any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research; interim analyses; and/or unsupported opinion.
Faculty may discuss information about pharmaceutical agents that is outside of FDA-approved labeling. This information is intended solely for CME and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information. | | Back to top | | | INTENDED AUDIENCE | This activity has been developed for cardiologists, surgeons, primary care physicians, nurses, and pharmacists involved in the management of patients with atrial fibrillation (AF) who require oral anticoagulant therapy. | | Back to top | | | PROGRAM GOAL | Through completion of this activity, participants will understand how to treat patients with AF who require anticoagulation therapy and how to monitor them. | | Back to top | | | EDUCATIONAL OBJECTIVES | After completing this activity and the post-test, participants should be able to:
- Discuss the incidence and risks associated with AF
- List high-risk characteristics of AF patients (eg, patient age, congestive heart failure, diabetes)
- List possible approaches to treatment of AF patients during cardioversion
- Understand the issues surrounding AF in various patient populations
- Understand the role of anticoagulation in patients with AF
Release Date of Activity: 3/15/2006
Expiration Date of Activity for AMA PRA Credit: 3/31/2008
Estimated Time to Complete This Activity: 1 | | Back to top | | | FINANCIAL SUPPORT | This CME activity is supported by an educational grant from sanofi-aventis U.S. | | Back to top | | | CME PLANNING COMMITTEE | Deepak L. Bhatt, MD
Geno J. Merli, MD
Andrea Natale, MD
Allan L. Klein, MD
Boris S. Lowe, BHB
Mina K. Chung, MD
Jack Hirsh, MD
Lawrence DeCaria, PharmD
Jennifer DiBenedetto | | Back to top | | | SPECIAL NEEDS | We encourage participation by all individuals. If you have any special needs, please contact Sharon Liuzza at 908-547-2178, or s.liuzza@elsevier.com for assistance.
Copyright © 2006 by Excerpta Medica, Inc., an Elsevier business. All rights reserved. Release date: May 2006 | | Back to top | | |
|
| | |
|
|
| |
|
|